Healthcare | January 08, 2025
HMPV update: States advised to strengthen awareness among masses regarding preventive measures
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
ICMR will continue to track trends in HMPV circulation throughout the year
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
Merck has also decided to end the favezelimab clinical development program
Subscribe To Our Newsletter & Stay Updated
